Table 2.
Comparison of baseline characteristics between EMM patients and non-EMM patients in the two clinical trials conducted in our center.
| Characteristics | EMM (n = 25) | non-EMM (n = 36) | p-Value |
|---|---|---|---|
| Age, yr, median (range) | 55 (34 - 70) | 53 (34 - 69) | 0.509 |
| Sex, n (%) | 0.353 | ||
| Male | 13 (52.0) | 23 (63.9) | |
| Female | 12 (48.0) | 13 (36.1) | |
| ECOG performance-status score | 1.000 | ||
| 0-1 | 23 (92.0) | 34 (94.4) | |
| 2-3 | 2 (8.0) | 2 (5.6) | |
| Time since diagnosis, yr, median (range) | 3.2 (0.8 - 12.6) | 2.9 (0.7 - 11.3) | 0.363 |
| Prior lines of therapy, median (range) | 4 (3 - 11) | 4 (3 - 10) | 0.114 |
| Durie-Salmon stage, n (%) | 0.145 | ||
| I | 1 (4.0) | 0 | |
| II | 0 | 3 (8.3) | |
| III | 22 (95.0) | 33 (91.7) | |
| ISS stage, n (%) | 0.288 | ||
| I | 7 (30.0) | 16 (44.4) | |
| II | 11 (48.0) | 10 (27.8) | |
| III | 5 (22.0) | 10 (27.8) | |
| Myeloma type, n (%) | 0.104 | ||
| IgG κ | 5 (20.0) | 8 (22.2) | |
| IgG λ | 9 (36.0) | 10 (27.8) | |
| IgA κ | 2 (8.0) | 3 (8.3) | |
| IgA λ | 0 | 2 (5.6) | |
| IgD λ | 1 (4.0) | 3 (8.3) | |
| Light chain κ | 0 | 6 (16.7) | |
| Light chain λ | 7 (28.0) | 2 (5.6) | |
| Non-secretor | 1 (4.0) | 2 (5.6) | |
| High risk cytogenetics, n (%)& | 6 (24.0) | 18 (50.0) | 0.041 |
| TP 53 mutations, n (%) | 3 (13.6) | 3 (9.1) | 0.674 |
| BCMA MFI on plasma cells, median (range) | 2417 (840 - 12516) | 1586 (303 - 51023) | 0.133 |
| CAR-T structure, n (%) | 0.192 | ||
| Murine | 18 (72.0) | 20 (55.6) | |
| Fully human | 7 (28.0) | 16 (44.4) |
EMM, extramedullary myeloma; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; ECOG, Eastern Cooperative Oncology Group; DS, Durie Salmon; ISS, International Staging System; MFI, Mean Fluorescence Intensity.
&Cytogenetic features were measured using florescence in situ hybridization. The probes include t(4;14), Del(17p), 1q21, t(14;16), Del (13q), t(11;14) and. High risk cytogenetic features (any t(4;14), Del(17p), and t(14;16)) evaluated with conventional cytogenetics or fluorescence in-situ hybridization (FISH).